Full Text Journal Articles by
Author Andrew Buchanan

Advertisement

Find full text journal articles






Brief Report: Changes in PrEP Use, Sexual Practice, and Use of Face Mask During Sex Among MSM During the Second Wave of COVID-19 in Melbourne, Australia.

Eric P F Chow, Jane S Hocking, Jason J Ong, Tiffany R Phillips, Tina Schmidt, Andrew Buchanan, Elena Rodriguez, Kate Maddaford, Christopher K Fairley,

<h4>Background</h4>A second wave of COVID-19 began in late June in Victoria, Australia. Stage 3 then Stage 4 restrictions were introduced in July-August. This study aimed to compare the use of pre-exposure prophylaxis (PrEP) and sexual practices among men who have sex with men taking PrEP between May-June (post-first lockdown) and ... Read more >>

J Acquir Immune Defic Syndr (Journal of acquired immune deficiency syndromes (1999))
[2021, 86(2):153-156]

Cited: 0 times

View full text PDF listing >>



Data mining patented antibody sequences

Konrad Krawczyk, Andrew Buchanan, Paolo Marcatili,

Patent literature should be a reflection of thirty years of engineering efforts in developing monoclonal antibody therapeutics. Such information is potentially valuable for rational antibody design. Patents however are not designed to convey scientific knowledge, but rather legal protection. It is unclear whether antibody information from patent documents, such as ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Evaluation of Patients with Insufficient Efficacy and/or Tolerability to Triptans for the Acute Treatment of Migraine: A Systematic Literature Review.

Elizabeth Leroux, Andrew Buchanan, Louise Lombard, Li Shen Loo, Daisy Bridge, Ben Rousseau, Natasha Hopwood, Brandy R Matthews, Uwe Reuter,

<h4>Introduction</h4>Use of triptans for acute treatment of migraine is associated with insufficient efficacy and/or tolerability in approximately 30-40% of people. We conducted a systematic literature review (SLR) to synthesize definitions, terminology, subsequent treatment outcomes, and characteristics associated with this subpopulation.<h4>Methods</h4>A comprehensive SLR was conducted to identify studies, published from Jan ... Read more >>

Adv Ther (Advances in therapy)
[2020, 37(12):4765-4796]

Cited: 0 times

View full text PDF listing >>



In vitro evolution of antibody affinity via insertional scanning mutagenesis of an entire antibody variable region.

Kalliopi Skamaki, Stephane Emond, Matthieu Chodorge, John Andrews, D Gareth Rees, Daniel Cannon, Bojana Popovic, Andrew Buchanan, Ralph R Minter, Florian Hollfelder,

We report a systematic combinatorial exploration of affinity enhancement of antibodies by insertions and deletions (InDels). Transposon-based introduction of InDels via the method TRIAD (transposition-based random insertion and deletion mutagenesis) was used to generate large libraries with random in-frame InDels across the entire single-chain variable fragment gene that were further ... Read more >>

Proc Natl Acad Sci U S A (Proceedings of the National Academy of Sciences of the United States of America)
[2020, 117(44):27307-27318]

Cited: 0 times

View full text PDF listing >>



Changing the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the COVID-19 Pandemic in Melbourne, Australia.

Eric P F Chow, Jane S Hocking, Jason J Ong, Tina Schmidt, Andrew Buchanan, Elena Rodriguez, Kate Maddaford, Prital Patel, Christopher K Fairley,

We surveyed 204 men who have sex with men (MSM) who were pre-exposure prophylaxis (PrEP) users. One in 4 daily PrEP users stopped taking PrEP during the COVID-19 pandemic, and 5% switched to on-demand PrEP. Most men reduced PrEP use because they stopped having casual sex and reduced the number ... Read more >>

Open Forum Infect Dis (Open forum infectious diseases)
[2020, 7(7):ofaa275]

Cited: 3 times

View full text PDF listing >>



In vitro Evolution of Antibody Affinity via Insertional Mutagenesis Scanning of an Entire Antibody Variable Region

Kalliopi Skamaki, Stephane Emond, Matthieu Chodorge, John Andrews, Gareth Rees, Daniel Cannon, Bojana Popovic, Andrew Buchanan, Ralph Minter, Florian Hollfelder,

We report the first systematic combinatorial exploration of affinity enhancement of antibodies by insertions and deletions (InDels). Transposon-based introduction of InDels via the method TRIAD was used to generate large libraries with random in-frame InDels across the entire scFv gene that were further recombined and screened by ribosome display. Knowledge ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.

Louise Lombard, Mallory Farrar, Wenyu Ye, Yongin Kim, Sarah Cotton, Andrew S Buchanan, James Jackson, Shivang Joshi,

BACKGROUND:Migraine is a chronic, disabling neurological disease characterized by moderate-to-severe headache pain with other symptoms, including nausea, vomiting, and photophobia. Triptans, while generally effective, are insufficiently efficacious in 30-40% of patients and poorly tolerated by or contraindicated in others. We assessed the impact of insufficient response to triptans on health-related ... Read more >>

J Headache Pain (The journal of headache and pain)
[2020, 21(1):41]

Cited: 3 times

View full text PDF listing >>



Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.

Richard B Lipton, Louise Lombard, Dustin D Ruff, John H Krege, Li Shen Loo, Andrew Buchanan, Thomas E Melby, Dawn C Buse,

BACKGROUND:Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT1F receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety ... Read more >>

J Headache Pain (The journal of headache and pain)
[2020, 21(1):20]

Cited: 2 times

View full text PDF listing >>



Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.

Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li Shen Loo, Mika Komori, Joshua Tobin,

<h4>Background</h4>Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated analyses evaluated the efficacy of lasmiditan in patients who reported a good or insufficient response to triptans and in those who ... Read more >>

Cephalalgia (Cephalalgia : an international journal of headache)
[2020, 40(1):19-27]

Cited: 4 times

View full text PDF listing >>



Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.

John H Krege, Paul B Rizzoli, Emily Liffick, Erin G Doty, Sherie A Dowsett, Jianing Wang, Andrew S Buchanan,

<h4>Background</h4>We assessed the safety profile of lasmiditan, a selective 5-HT<sub>1F</sub> receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine.<h4>Methods</h4>SAMURAI and SPARTAN were Phase 3 double-blind studies of patients with migraine, randomized to oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo to be taken within 4 ... Read more >>

Cephalalgia (Cephalalgia : an international journal of headache)
[2019, 39(8):957-966]

Cited: 6 times

View full text PDF listing >>



Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.

Stewart J Tepper, John H Krege, Louise Lombard, Josephine K Asafu-Adjei, Sherie A Dowsett, Joel Raskin, Andrew S Buchanan, Deborah I Friedman,

<h4>Trial design</h4>SAMURAI and SPARTAN were double-blind, placebo-controlled Phase 3 studies conducted in the United States, as well as the United Kingdom and Germany (SPARTAN only). Individuals with migraine were randomized to receive oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo within 4 hours of onset of a migraine attack. The aim ... Read more >>

Headache (Headache)
[2019, 59(7):1052-1062]

Cited: 2 times

View full text PDF listing >>



Interactions Between the Gravitostat and the Fibroblast Growth Factor System for the Regulation of Body Weight.

Vilborg Palsdottir, Sara H Windahl, Daniel A Hägg, Hanna Keantar, Jakob Bellman, Andrew Buchanan, Tristan J Vaughan, Daniel Lindén, John-Olov Jansson, Claes Ohlsson,

Both fibroblast growth factors (FGFs), by binding to FGF receptors (FGFRs), and activation of the gravitostat, by artificial loading, decrease the body weight (BW). Previous studies demonstrate that both the FGF system and loading have the capacity to regulate BW independently of leptin. The aim of the current study was ... Read more >>

Endocrinology (Endocrinology)
[2019, 160(5):1057-1064]

Cited: 2 times

View full text PDF listing >>



Experimentally guided computational antibody affinity maturation with de novo docking, modelling and rational design.

Daniel A Cannon, Lu Shan, Qun Du, Lena Shirinian, Keith W Rickert, Kim L Rosenthal, Martin Korade, Lilian E van Vlerken-Ysla, Andrew Buchanan, Tristan J Vaughan, Melissa M Damschroder, Bojana Popovic,

Antibodies are an important class of therapeutics that have significant clinical impact for the treatment of severe diseases. Computational tools to support antibody drug discovery have been developing at an increasing rate over the last decade and typically rely upon a predetermined co-crystal structure of the antibody bound to the ... Read more >>

PLoS Comput Biol (PLoS computational biology)
[2019, 15(5):e1006980]

Cited: 3 times

View full text PDF listing >>



Engineering of a GLP-1 analogue peptide/anti-PCSK9 antibody fusion for type 2 diabetes treatment.

Matthieu Chodorge, Anthony J Celeste, Joseph Grimsby, Anish Konkar, Pia Davidsson, David Fairman, Lesley Jenkinson, Jacqueline Naylor, Nicholas White, Jonathan C Seaman, Karen Dickson, Benjamin Kemp, Jennifer Spooner, Emmanuel Rossy, David C Hornigold, James L Trevaskis, Nicholas J Bond, Timothy B London, Andrew Buchanan, Tristan Vaughan, Cristina M Rondinone, Jane K Osbourn,

Type 2 diabetes (T2D) is a complex and progressive disease requiring polypharmacy to manage hyperglycaemia and cardiovascular risk factors. However, most patients do not achieve combined treatment goals. To address this therapeutic gap, we have developed MEDI4166, a novel glucagon-like peptide-1 (GLP-1) receptor agonist peptide fused to a proprotein convertase ... Read more >>

Sci Rep (Scientific reports)
[2018, 8(1):17545]

Cited: 2 times

View full text PDF listing >>



Computational Design of Epitope-Specific Functional Antibodies.

Guy Nimrod, Sharon Fischman, Mark Austin, Asael Herman, Feenagh Keyes, Olga Leiderman, David Hargreaves, Marek Strajbl, Jason Breed, Shelley Klompus, Kevin Minton, Jennifer Spooner, Andrew Buchanan, Tristan J Vaughan, Yanay Ofran,

The ultimate goal of protein design is to introduce new biological activity. We propose a computational approach for designing functional antibodies by focusing on functional epitopes, integrating large-scale statistical analysis with multiple structural models. Machine learning is used to analyze these models and predict specific residue-residue contacts. We use this ... Read more >>

Cell Rep (Cell reports)
[2018, 25(8):2121-2131.e5]

Cited: 4 times

View full text PDF listing >>



Monoclonal antibody targeting of fibroblast growth factor receptor 1c causes cardiac valvulopathy in rats.

Nicholas Buss, Jean-Martin Lapointe, Lolke de Haan, Sally Price, Andrea Ahnmark, Lorraine Irving, Andrew Buchanan, Feenagh Keyes, Pia Davidsson, Rakesh Dixit, Daniel Lindén,

Fibroblast Growth Factors (FGFs) and their receptors (FGFRs) have been proposed as potential drug targets for the treatment of obesity. The aim of this study was to assess the potential toxicity in rats of three anti-FGFR1c mAbs with differential binding activity prior to clinical development. Groups of male rats received ... Read more >>

Toxicol Appl Pharmacol (Toxicology and applied pharmacology)
[2018, 355:147-155]

Cited: 1 time

View full text PDF listing >>



Beyond mere pill taking: SMS reminders for HIV treatment adherence delivered to mobile phones of clients in a community support network in Australia.

Limin Mao, Andrew Buchanan, Horas Tze Hoo Wong, Asha Persson,

SMS reminders sent to personal mobiles are increasingly used by clinical services to promote patient engagement, including adherence to antiretroviral treatment (ART) for HIV. From August to September 2015, a 6-week, randomised SMS reminder for ART adherence intervention was implemented among 98 HIV-positive clients of Australian's largest HIV charitable organisation ... Read more >>

Health Soc Care Community (Health & social care in the community)
[2018, 26(4):486-494]

Cited: 6 times

View full text PDF listing >>



Antibody-Drug Conjugates Bearing Pyrrolobenzodiazepine or Tubulysin Payloads Are Immunomodulatory and Synergize with Multiple Immunotherapies.

Jonathan Rios-Doria, Jay Harper, Raymond Rothstein, Leslie Wetzel, Jon Chesebrough, Allison Marrero, Cui Chen, Patrick Strout, Kathy Mulgrew, Kelly McGlinchey, Ryan Fleming, Binyam Bezabeh, John Meekin, David Stewart, Maureen Kennedy, Philip Martin, Andrew Buchanan, Nazzareno Dimasi, Emil Michelotti, Robert Hollingsworth,

Immunogenic cell death (ICD) is the process by which certain cytotoxic drugs induce apoptosis of tumor cells in a manner that stimulates the immune system. In this study, we investigated whether antibody-drug conjugates (ADCS) conjugated with pyrrolobenzodiazepine dimer (PBD) or tubulysin payloads induce ICD, modulate the immune microenvironment, and could ... Read more >>

Cancer Res (Cancer research)
[2017, 77(10):2686-2698]

Cited: 13 times

View full text PDF listing >>



Rate of Asparagine Deamidation in a Monoclonal Antibody Correlating with Hydrogen Exchange Rate at Adjacent Downstream Residues.

Jonathan J Phillips, Andrew Buchanan, John Andrews, Matthieu Chodorge, Sudharsan Sridharan, Laura Mitchell, Nicole Burmeister, Alistair D Kippen, Tristan J Vaughan, Daniel R Higazi, David Lowe,

Antibodies are an important class of drugs, comprising more than half of all new FDA approvals. Therapeutic antibodies must be chemically stable both in storage and in vivo, following administration to patients. Deamidation is a major degradation pathway for all natural and therapeutic proteins circulating in blood. Here, the linkage ... Read more >>

Anal Chem (Analytical chemistry)
[2017, 89(4):2361-2368]

Cited: 7 times

View full text PDF listing >>



Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain.

Nazzareno Dimasi, Ryan Fleming, Kris F Sachsenmeier, Binyam Bezabeh, Carl Hay, Jincheng Wu, Erin Sult, Saravanan Rajan, Li Zhuang, Peter Cariuk, Andrew Buchanan, Michael A Bowen, Herren Wu, Changshou Gao,

We developed an IgG1 domain-tethering approach to guide the correct assembly of 2 light and 2 heavy chains, derived from 2 different antibodies, to form bispecific monovalent antibodies in IgG1 format. We show here that assembling 2 different light and heavy chains by sequentially connecting them with protease-cleavable polypeptide linkers ... Read more >>

MAbs (mAbs)
[2017, 9(3):438-454]

Cited: 1 time

View full text PDF listing >>



Characterization and application of two RANK-specific antibodies with different biological activities.

Mélanie Chypre, Jonathan Seaman, Olga G Cordeiro, Laure Willen, Kathryn A Knoop, Andrew Buchanan, Richard C A Sainson, Ifor R Williams, Hideo Yagita, Pascal Schneider, Christopher G Mueller,

Antibodies play an important role in therapy and investigative biomedical research. The TNF-family member Receptor Activator of NF-κB (RANK) is known for its role in bone homeostasis and is increasingly recognized as a central player in immune regulation and epithelial cell activation. However, the study of RANK biology has been ... Read more >>

Immunol Lett (Immunology letters)
[2016, 171:5-14]

Cited: 2 times

View full text PDF listing >>



Defining Regions in Multiregional Clinical Trials: An Analytical Approach to Considering Impact of Intrinsic and Extrinsic Factors.

Yoko Tanaka, Andrew Buchanan, Sarah Lipsius, Ekopimo Okon Ibia, Michael Rabbia, Bruce Binkowitz,

<h4>Background</h4>This article describes follow-up work extended from Tanaka et al (2011) in defining the region in multiregional clinical trials (MRCTs). The previous paper advocated a systematic approach to defining regions and recommended the sponsor to think through carefully, prespecify, and justify any regional definitions as well as obtain regulatory concurrence ... Read more >>

Ther Innov Regul Sci (Therapeutic innovation & regulatory science)
[2016, 50(1):91-100]

Cited: 0 times

View full text PDF listing >>



Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized Trials.

Linda A Wietecha, David B Clemow, Andrew S Buchanan, Joel L Young, Elias H Sarkis, Robert L Findling,

<h4>Introduction</h4>Changes in the magnitude of efficacy throughout 26 weeks of atomoxetine treatment, along with impact of dosing, were evaluated in adults with ADHD from two randomized, double-blind, placebo-controlled studies.<h4>Aims</h4>Pooled placebo (n = 485) and atomoxetine (n = 518) patients, dosed 25, 40, 60, 80 (target dose), or 100 mg daily, ... Read more >>

CNS Neurosci Ther (CNS neuroscience & therapeutics)
[2016, 22(7):546-557]

Cited: 1 time

View full text PDF listing >>



Structural and functional characterization of a specific antidote for ticagrelor.

Andrew Buchanan, Philip Newton, Susanne Pehrsson, Tord Inghardt, Thomas Antonsson, Peder Svensson, Tove Sjögren, Linda Öster, Annika Janefeldt, Ann-Sofie Sandinge, Feenagh Keyes, Mark Austin, Jennifer Spooner, Peter Gennemark, Mark Penney, Garnet Howells, Tristan Vaughan, Sven Nylander,

Ticagrelor is a direct-acting reversibly binding P2Y12 antagonist and is widely used as an antiplatelet therapy for the prevention of cardiovascular events in acute coronary syndrome patients. However, antiplatelet therapy can be associated with an increased risk of bleeding. Here, we present data on the identification and the in vitro ... Read more >>

Blood (Blood)
[2015, 125(22):3484-3490]

Cited: 30 times

View full text PDF listing >>



Evaluation of strategies to control Fab light chain dimer during mammalian expression and purification: A universal one-step process for purification of correctly assembled Fab.

Jennifer Spooner, Jenny Keen, Kalpana Nayyar, Neil Birkett, Nicholas Bond, David Bannister, Natalie Tigue, Daniel Higazi, Benjamin Kemp, Tristan Vaughan, Alistair Kippen, Andrew Buchanan,

Fabs are an important class of antibody fragment as both research reagents and therapeutic agents. There are a plethora of methods described for their recombinant expression and purification. However, these do not address the issue of excessive light chain production that forms light chain dimers nor do they describe a ... Read more >>

Biotechnol Bioeng (Biotechnology and bioengineering)
[2015, 112(7):1472-1477]

Cited: 3 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2544 s